Avemar (MSC) is a nontoxic fermented wheat germ extract demonstrated to have antitumor effects. Avemar has the potential to significantly improve the survival rate in patients suffering from malignant colon tumors. We studied its effects in the HT-29 human colon carcinoma cell line. Avemar had an inhibiting effect on colonies of HT-29 cells with an IC50 value of 118 μg/ml (7 days of incubation); this value could be decreased to 100 and 75 μg/ml in the presence of vitamin C. In the cell line examined, Avemar induced both necrosis and apoptosis, as demonstrated by Hoechst/propldium iodide staining. The incubation of cells with 3200 μg/ml Avemar for 24 hrs caused necrosis in 28% and the induction of apoptosis in 22% of the cells. Avemar inhibited the cell-cycle progression of HT-29 cells in the G1 phase of the cell cycle. In addition, Avemar inhibited the activity of the key enzyme of de novo DNA synthesis, ribonucleotide reductase. In addition, we determined the effects of Avemar on the activity of cyclooxygenase-1 and -2. Both enzymes were significantly inhibited by Avemar with IC50 values of 100 and 300 μg/ml, respectively. We outline new explanations for its antitumor activity, which might serve as the basis for further studies using Avemar.
Fajka-BojaR, HidvégiM, ShoenfeldY, IonG, DemydenkoD, Tömösközi-FarkasR, VizierC, TelekesA, ResetárÁ, MonostoriÉ. Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol20: 563–570, 2002.
4.
HidvégiM, RásóE, Tömösközi-FarkasR, PakuS, LapisK, SzendeB. Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals. Anticancer Res18: 2353–2358, 1998.
5.
SzendeB, RásóE, HidvégiM, Tömösközi-FarkasR, PakuS, PrónaiL, BocsiJ, LapisK. A new benzoquinone-containing antimetastatic product [English translation]. Orv Hetil139: 2893–2897, 1998.
6.
HidvégiM, RásóE, Tömösközi-FarkasR, SzendeB, PakuS, PrónaiL, BocsiJ, LapisK. MSC, a new benzoquinone-containing natural product with antimetastatic effect. Cancer Biother Radiopharm14: 277–289, 1999.
7.
EhrenfeldM, BlankM, ShoenfeldY, HidvégiM. Avemar (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease. Lupus10: 622–627, 2003.
JakabF, MayerÁ, HoffmannA, HidvégiM. First clinical data of a natural immunomodulator in colorectal cancer. Hepatogastroenterology47: 393–395, 2000.
10.
JakabF, ShoenfeldY, BaloghÁ, NichelattiM, HoffmannA, KahánZ, LapisK, MayerÁ, SápyP, SzentpeéteryF, TelekesA, ThurzóL, VágvölgyiA, HidvégiM. A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer89: 465–469, 2003.
11.
GarrettC, SantiDV. A rapid and sensitive high-pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem99: 268–273, 1979.
12.
ElfordHL, FreeseM, PassamaniE, MorrisHP. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem245: 5228–5233, 1970.
13.
TakedaE, WeberG. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci28: 1007–1014, 1981.
14.
ThunMJ, NamboodiriMM, HeathCWJr.. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med325: 1593–1596, 1991.
15.
HarrisRE, ChlebowskiRT, JacksonRD, FridDJ, AscenseoJL, AndersonG, LoarA, RodaboughRJ, WhiteE, McTiernanA, Women's Health Initiative.Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res63: 6096–6101, 2003.
16.
Report. Acute oral toxicity study of Avemar in mouse. Code: 9901. Department of Pharmacology and Toxicology, University of Veterinary Science, Budapest, 1999 (Biromedicina First Hungarian Corporation for Cancer Research and Oncology on file).
17.
Report. Acute oral toxicity study of Avemar in rats. Code: 9902. Department of Pharmacology and Toxicology, University of Veterinary Science, Budapest, 1999 (Biromedicina First Hungarian Corporation for Cancer Research and Oncology on file).
18.
Report. Subacute oral toxicity study of Avemar. Code: 0001. Department of Pharmacology and Toxicology, Szent István University, School of Veterinary Science, Budapest, 2000 (Biromedicina First Hungarian Corporation for Cancer Research and Oncology on file).
19.
SzendeB, MarcsekZ, KocsisZ, TompaA. Effect of simultaneous administration of Avemar and cytostatic drugs on viability of cell cultures, growth of experimental tumors, and survival of tumor-bearing mice. Cancer Biother Radiopharm19: 343–349, 2004.
20.
DemidovLV, ManzjukLV, KharkevitchGY, ArtamonovaEV, PirogovaNA. Antimetastatic effect of Avemar in high-risk melanoma patients (abstract P868). In: Program of the 18th UICC International Cancer Congress, June 30– July 5, 2002, Oslo, Norway. Int J Cancer100(Suppl 13):408, 2002.
21.
HidvégiM, MoldvayJ, LapisK, AjkayZ. Fermented wheat germ extract improves quality of life in lung cancer patients [English translation]. Medicus Anonymus/Pulmono11(Suppl 1): 13–14, 2003.
